Theranos founder convicted of fraud on investors; sentenced to 11 years
Theranos Inc. · Health technology (blood testing)
The case in brief
Visible before detection
Checks that could have surfaced it, on hindsight
Third-party confirmation
Would have asked the Department of Defense and named partners to confirm the claimed deployments.
Can mislead when: Counterparties can collude or ignore requests. A non-response is logged as a gap, never as a pass.
Operating-metric verification
Would have tested the claimed test menu and volumes against what the device actually ran.
Can mislead when: Contract staff do not appear in EPFO. Vahan access needs licensed APIs. Some businesses have no physical trace.
Governance signals
Would have flagged the CEO's super-majority voting control.
Can mislead when: Private companies file late, so these signals are lagging. Kubr uses them to support other flags, not to prove anything alone.
Where Kubr services would have helped
Valuation context
Offered in India- C11 Would have flagged the CEO's super-majority voting control.
Portfolio monitor
Offered in India- C10 Would have tested the claimed test menu and volumes against what the device actually ran.
- C11 Would have flagged the CEO's super-majority voting control.
Verified Snapshot
Offered in India- C11 Would have flagged the CEO's super-majority voting control.
Financial diligence
Offered in India- C10 Would have tested the claimed test menu and volumes against what the device actually ran.
Mapped from the checks each service runs. A hindsight reading of public records, not a promise that the failure would have been found.
Same pattern
A summary of public documents. It reports what the sources say. It is not Kubr's finding and not a statement of guilt.